PARTNER试验:外科与经股动脉导管主动脉瓣置换术后卒中的比较
该研究对PARTNER试验中1204对严重主动脉瓣狭窄患者进行倾向性匹配,比较SAVR与TF-TAVR术后30天神经事件及48个月内的卒中风险。结果显示两组30天卒中发生率相似,但TF-TAVR的30天重大卒中发生率更低;重大卒中与术后1年生活质量下降相关。
要点
- TF-TAVR与SAVR的30天卒中发生率相似(5.1% vs 3.7%,p=0.09)。
- TF-TAVR的30天重大卒中发生率低于SAVR(2.2% vs 3.9%,p=0.018)。
- 重大卒中与术后1年生活质量下降相关。
核心结论
- 尽管早期(术后<1天)神经风险峰值相似,SAVR与TF-TAVR相比早期重大卒中风险更高。
研究设计与样本
- 倾向性匹配研究,纳入PARTNER试验中1204对严重主动脉瓣狭窄患者,比较SAVR与TF-TAVR。
主要发现
- 30天卒中发生率:SAVR 5.1% vs TF-TAVR 3.7%(p=0.09),差异无统计学意义。
- 30天重大卒中发生率:SAVR 3.9% vs TF-TAVR 2.2%(p=0.018),TF-TAVR更低。
- 两组卒中风险均在术后第1天达峰值,随后至48个月维持近乎恒定的低水平风险。
- 重大卒中与1年生活质量下降相关:SAVR组KCCQ中位数无重大卒中79 vs 有重大卒中64(p=0.03);TF-TAVR组78 vs 60(p=0.04)。
临床怎么用
- 对于严重主动脉瓣狭窄患者,选择TF-TAVR可能降低早期重大卒中风险。
- 术后应关注卒中对生活质量的长期影响,并采取围术期策略减少卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transfemoral-transcatheter aortic valve replacement (TF-TAVR) is increasingly used to treat aortic stenosis, but risk of post-procedure stroke is uncertain. OBJECTIVES: The purpose of this study was to assess stroke risk and its association with quality of life after surgical aortic valve replacement (SAVR) versus TF-TAVR. METHODS: The authors performed a propensity-matched study of 1,204 pairs of patients with severe aortic stenosis treated with SAVR versus TF-TAVR in the PARTNER (Placement of AoRTic TraNscathetER Valves) trials from April 2007 to October 2014. Outcomes were: 1) 30-day neurological events; 2) time-varying risk of neurological events early (≤7 days) and late (7 days to 48 months) post-procedure; and 3) association between stroke and quality of life 1 year post-procedure by the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score. RESULTS: Thirty-day stroke (5.1% vs. 3.7%; p = 0.09) was similar, but 30-day major stroke (3.9% vs. 2.2%; p = 0.018) was lower after TF-TAVR than SAVR. In both groups, risk of stroke peaked in the first post-procedure day, followed by a near-constant low-level risk to 48 months. Major stroke was associated with a decline in quality of life at 1 year in both SAVR (KCCQ score median [15th, 85th percentile]: 79 [53, 94] without major stroke vs. 64 [30, 94] with major stroke; p = 0.03) and TF-TAVR (78 [49, 96] without major stroke vs. 60 [8, 99] with major stroke; p = 0.04). CONCLUSIONS: Despite similar early-peaking (<1 day post-procedure) neurological risk profiles, SAVR is associated with a higher risk of early major stroke than TF-TAVR. Periprocedural strategies are needed to reduce stroke risk after aortic valve procedures. (Placement of AoRTic TraNscathetER Valve Trial [PARTNER]; NCT00530894).
引用
- Kapadia SR, Huded CP, Kodali SK, et al. Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. J Am Coll Cardiol. 2018. PMID: 30442284. doi:10.1016/j.jacc.2018.08.2172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。